See more : Moneysupermarket.com Group PLC (MONY.L) Income Statement Analysis – Financial Results
Complete financial analysis of BGI Genomics Co., Ltd. (300676.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BGI Genomics Co., Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Electronic Arts Inc. (EA) Income Statement Analysis – Financial Results
- Transfar Zhilian Co., Ltd. (002010.SZ) Income Statement Analysis – Financial Results
- Limitless Venture Group Inc. (LVGI) Income Statement Analysis – Financial Results
- Suzuden Corporation (7480.T) Income Statement Analysis – Financial Results
- eBullion, Inc. (EBML) Income Statement Analysis – Financial Results
BGI Genomics Co., Ltd. (300676.SZ)
About BGI Genomics Co., Ltd.
BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.35B | 7.05B | 6.77B | 8.40B | 2.80B | 2.54B | 2.10B | 1.71B | 1.32B | 1.13B | 1.05B | 794.84M |
| Cost of Revenue | 2.18B | 3.36B | 2.84B | 3.35B | 1.30B | 1.13B | 902.20M | 711.25M | 586.20M | 612.14M | 463.34M | 415.36M |
| Gross Profit | 2.17B | 3.69B | 3.93B | 5.04B | 1.50B | 1.40B | 1.19B | 1.00B | 732.50M | 519.84M | 584.04M | 379.48M |
| Gross Profit Ratio | 49.90% | 52.36% | 58.09% | 60.07% | 53.56% | 55.35% | 56.95% | 58.44% | 55.55% | 45.92% | 55.76% | 47.74% |
| Research & Development | 528.92M | 535.79M | 487.15M | 619.64M | 317.32M | 260.92M | 174.31M | 176.72M | 101.76M | 130.64M | 50.60M | 39.91M |
| General & Administrative | 128.58M | 140.85M | 156.79M | 126.25M | 72.59M | 55.66M | 50.22M | 68.81M | 43.38M | 37.67M | 137.95M | 106.07M |
| Selling & Marketing | 549.69M | 1.61B | 1.24B | 1.08B | 618.74M | 514.28M | 401.86M | 327.61M | 240.55M | 213.92M | 220.85M | 136.12M |
| SG&A | 1.51B | 1.75B | 1.40B | 1.20B | 691.33M | 569.93M | 452.08M | 396.42M | 283.93M | 251.59M | 358.80M | 242.20M |
| Other Expenses | -13.59M | 151.73M | 200.85M | 406.67M | 87.51M | -3.50M | -7.37M | 29.01M | 25.97M | 22.19M | 6.01M | 1.92M |
| Operating Expenses | 2.02B | 2.44B | 2.08B | 2.23B | 1.10B | 911.00M | 708.49M | 673.09M | 467.18M | 457.46M | 365.39M | 253.86M |
| Cost & Expenses | 4.20B | 5.79B | 4.92B | 5.58B | 2.40B | 2.04B | 1.61B | 1.38B | 1.05B | 1.07B | 828.73M | 669.22M |
| Interest Income | 152.04M | 116.83M | 44.34M | 18.10M | 9.77M | 6.34M | 2.32M | 989.86K | 2.14M | 1.22M | 7.07M | 15.69M |
| Interest Expense | 91.56M | 100.76M | 104.72M | 89.04M | 5.73M | 270.55K | 307.17K | 131.95K | 770.34K | 298.16K | 0.00 | 0.00 |
| Depreciation & Amortization | 436.84M | 487.67M | 396.42M | 328.22M | 263.81M | 191.91M | 135.29M | 111.89M | 88.54M | 91.00M | 41.00M | 19.50M |
| EBITDA | 643.93M | 1.56B | 2.14B | 2.76B | 600.68M | 671.97M | 636.58M | 527.55M | 432.78M | 180.47M | 259.66M | 145.12M |
| EBITDA Ratio | 14.80% | 29.98% | 35.28% | 36.79% | 24.05% | 28.85% | 31.21% | 31.95% | 34.20% | 15.35% | 25.04% | 18.50% |
| Operating Income | 150.65M | 1.66B | 1.82B | 2.50B | 330.13M | 478.42M | 503.51M | 382.34M | 303.91M | 53.56M | 199.02M | 104.38M |
| Operating Income Ratio | 3.46% | 23.55% | 26.94% | 29.75% | 11.79% | 18.86% | 24.03% | 22.34% | 23.05% | 4.73% | 19.00% | 13.13% |
| Total Other Income/Expenses | -35.11M | -379.03M | -188.63M | -55.88M | -1.94M | -3.50M | -8.00M | 28.97M | 20.28M | 21.42M | -13.99M | -19.40M |
| Income Before Tax | 115.54M | 1.01B | 1.75B | 2.44B | 328.19M | 474.92M | 496.13M | 409.69M | 324.19M | 74.91M | 204.66M | 106.22M |
| Income Before Tax Ratio | 2.66% | 14.29% | 25.80% | 29.08% | 11.72% | 18.72% | 23.68% | 23.94% | 24.58% | 6.62% | 19.54% | 13.36% |
| Income Tax Expense | 21.85M | 197.51M | 268.19M | 340.24M | 49.67M | 67.07M | 72.45M | 59.67M | 52.13M | 16.38M | 31.99M | 20.87M |
| Net Income | 92.90M | 802.77M | 1.46B | 2.09B | 276.33M | 386.65M | 398.09M | 332.69M | 262.10M | 28.12M | 135.88M | 81.73M |
| Net Income Ratio | 2.14% | 11.39% | 21.60% | 24.89% | 9.87% | 15.24% | 19.00% | 19.44% | 19.88% | 2.48% | 12.97% | 10.28% |
| EPS | 0.23 | 1.96 | 3.56 | 5.25 | 0.69 | 0.97 | 1.05 | 0.92 | 0.77 | 0.11 | 1.66 | 1.32 |
| EPS Diluted | 0.23 | 1.96 | 3.55 | 5.24 | 0.69 | 0.97 | 1.05 | 0.92 | 0.77 | 0.11 | 1.66 | 1.32 |
| Weighted Avg Shares Out | 409.91M | 409.91M | 410.05M | 398.00M | 400.10M | 400.09M | 379.13M | 361.62M | 340.39M | 255.64M | 81.86M | 61.92M |
| Weighted Avg Shares Out (Dil) | 412.34M | 409.91M | 411.68M | 399.27M | 400.10M | 400.09M | 379.13M | 361.62M | 340.39M | 255.64M | 81.86M | 61.92M |
Source: https://incomestatements.info
Category: Stock Reports